Proteomic identification of potential prognostic biomarkers in resectable pancreatic ductal adenocarcinoma

Abstract

Pancreatic cancer is a devastating disease with a mortality rate almost identical with its incidence. In this context, the investigation of the pancreatic cancer proteome has gained considerable attention because profiles of proteins may be able to identify disease states and progression more accurately. Therefore, our objective was to investigate the changes in the proteome of patients suffering from pancreatic ductal adenocarcinoma (PDAC) by a comprehensive quantitative approach. Comparative proteomic profiling by label-free LC-MS/MS analysis of nine matched pairs of tumor and nontumor pancreas samples was used to identify differences in protein levels characteristic for PDAC. In this analysis, 488 proteins were quantified by at least two peptides of which 99 proteins displayed altered levels in PDAC (p < 0.01, fold change >1.3). Screening of data revealed a number of molecules that had already been related to PDAC such as galectin-1 (LEG1), major vault protein, adenylyl cyclase-associated protein 1 (CAP1), but also a potential new prognostic biomarker prolargin (PRELP). The Kaplan-Meier survival analysis revealed a significant correlation of protein abundance of PRELP with postoperative survival of patients with PDAC. For selected proteins the findings were verified by targeted proteomics (SRM), validated by immunohistochemistry and Western blotting and their value as candidate biomarkers is discussed.

Secretomic profiling of cells from hollow fiber bioreactor reveals PSMA3 as a potential cholangiocarcinoma biomarker

“…The analysis was performed on 95 proteins with 2-fold higher expression in the HFB system when compared to those in the MNC system. Upregulated proteins were selected for this analysis because they should be more suitable as for potential biomarkers (22). The upregulated proteins could form at least three clusters of the interaction networks as shown in Fig.…”

Proteins Differentially Expressed in the Pancreas of Hepatic Alcohol Dehydrogenase–Deficient Deer Mice Fed Ethanol For 3 Months

“…Previous proteomic studies in pancreatic tissue were mainly focused on finding biomarkers of pancreatic cancer 31,32 . At least 40% of the differentially expressed proteins were common in chronic pancreatitis and pancreatic ductal adenocarcinoma (PDAC), a common pancreatic cancer 33,34 .…”

An Integrated Meta-Analysis of Secretome and Proteome Identify Potential Biomarkers of Pancreatic Ductal Adenocarcinoma

“…We performed an integrative meta-analysis on pancreatic cancer secretome and proteome data to identify clinically relevant diagnostic and prognostic biomarkers. According to the meta-analysis study design and inclusion and exclusion criteria (Figure 1), 20 secretome studies and 35 proteome studies in pancreatic cancer were selected, which reported protein data obtained by mass spectrometry (Tables 1 and 2) [3,6,29,34,37,41,43,[45][46][47]. These data identified 782 proteins in pancreatic cancer secretome and 517 proteins in pancreatic ductal adenocarcinoma tumor samples.…”